Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on February 6, 2024, to announce its fourth-quarter 2023 financial results. While the filing itself is brief and primarily references an attached press release (Exhibit 99.1), the core information relates to the company's performance during the last quarter of 2023. Investors should review the furnished press release for detailed financial figures, including revenue, earnings per share, and any forward-looking guidance provided by management. This report serves as the official channel for disclosing these key financial metrics, which are crucial for assessing the company's operational success, profitability, and overall financial health. The filing indicates that the detailed results and commentary are available in the press release, making it the primary source for understanding EW's recent financial standing and future outlook.
Key Highlights
- 1Edwards Lifesciences (EW) reported its fourth-quarter 2023 financial results on February 6, 2024, via an 8-K filing.
- 2The 8-K filing incorporates by reference a press release (Exhibit 99.1) containing the detailed financial results.
- 3Investors are directed to the press release for specific financial data, including revenue and earnings.
- 4The filing confirms that the information furnished is for disclosure purposes and is not deemed 'filed' under the Securities Exchange Act of 1934.
- 5This report serves as the official notification of the company's Q4 2023 performance.
- 6The event date for the results was February 5, 2024, with the filing date on February 5, 2024 (though the press release date is February 6, 2024, as noted in Item 2.02).